Solitary fibrous tumor of all sites: outcome of late recurrences in 14 patients

Clinical Sarcoma Research

Paolo G Casali⁴  Silvana Pilotti³  Michela Libertini⁴  Andrea Marrari⁴  Salvatore Provenzano⁴  Leonardo Duranti¹  Ugo Pastorino¹  Alessandro Gronchi¹  Angelo P Dei Tos²  Valentina Mauro³  Silvia Stacchiotti⁴  Giacomo G Baldi⁴ 

[1] Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, Milan, 20133, Italy;Department of Anatomic Pathology, General Hospital of Treviso, P.zza Ospedale 1, Treviso, 31100, Italy;Department of Pathology, Experimental Molecular Pathology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, Milan, 20133, Italy;Department of Cancer Medicine, Adult Sarcoma Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, Milan, 20133, Italy

关键词: Late recurrence;    Outcome;    Hemangiopericytoma;    Solitary fibrous tumor;    Sarcoma;   

Others  :  861483
DOI  :  10.1186/2045-3329-3-4

 received in 2013-01-14, accepted in 2013-03-19,  发布年份 2013

【 摘 要 】

Background

We explore the pattern of late recurrence (LR) in solitary fibrous tumor (SFT), focusing on histopathologic characteristics, clinical presentation and patients (pts) outcome.

Methods

Clinical records of all pts with confirmed pathologic diagnosis of SFT treated at our Institution from 2005 to 2011 were reviewed. We analysed the data of pts who relapsed ≥10 years after initial diagnosis.

Results

A total of 14 pts were identified. The primary site of origin was pleura (5 pts), pelvis (4 pts), head and neck (3 pts) and retroperitoneum (2 pts). Primary tumor was a typical SFT in 5 and a malignant SFT in 7 out of 12 pts whose tumor tissue was available for revision. The median time to first recurrence was 12 years (range 10–23). The first relapse was local in 11 cases, distant in 3. Five pts later developed distant metastases. Four out of 5 cases of typical SFT developed distant metastases in spite of their initial benign aspect. No patient was disease-free at the time of the analyses.

Conclusion

Our series suggests that LR can occur in SFT and some cases can behave aggressively even in the absence of any primary morphologic evidence of malignancy. A prolonged follow-up may be advisable.

【 授权许可】

   
2013 Baldi et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Klemperer P, Rabin CB: Primary neoplasms of the pleura: a report of five cases. Arch Pathol 1931, 11:385-412.
• [2]Chan JK: Solitary fibrous tumour-everywhere, and a diagnosis in vogue. Histopathology 1997, 31:568-76. Dec
• [3]Fletcher CDM: The evolving classification of soft tissue tumours: an update based on the new WHO classification. Histopathology 2006, 48:3-12.
• [4]Louis DN, Ohgaki H, Wiestler OD, Cavanee WK (Eds): WHO classification of tumours of the central nervous system. In World Health Organization Classification of Tumours. 4th edition. Lyon: International Agency for Reasearch on Cancer; 2007.
• [5]Gengler C, Guillou L: Solitary fibrous tumor and hemangiopericytoma: evolution of a concept. Histopathology 2006, 28:67-74.
• [6]Fletcher CDM, Bridge JA, Hogendoorn P, Martens F: World Health Organization (WHO) Classification of Tumours of Soft tissue and Bone. Pathology and Genetics. Lyon: IARC Press; 2013.
• [7]Park MS, Araujo DM: New insights into the hemangiopericytoma/solitary fibrous tumor spectrum of tumors. Curr Opin Oncol 2009, 21:327-31.
• [8]Fletcher CDM, Unni KK, Mertens F: Tumours of soft tissue and bone. Pathology and Genetics. In: WHO Classifications of Tumours. Eur J Surg Oncol 2009, 35:994-8.
• [9]Pitluk HC, Conn J Jr: Hemangiopericytoma. Literature review and clinical presentations. Am J Surg 1979, 137:413-6.
• [10]Mosquera JM, Fletcher CD: Expanding the spectrum of malignant progression in solitary fibrous tumors: a study of 8 cases with a discrete anaplastic component–is this dedifferentiated SFT? Am J Surg Pathol 2009, 33:1314-21.
• [11]Guthrie BL, Ebersold MJ, Scheithauer BW, Shaw EG: Meningeal hemangiopericytoma: histopathological features, treatment, and long-term follow-up of 44 cases. Neurosurgery 1989, 25:514-22.
• [12]Spitz FR, Bouvet M, Pisters PW, Pollock RE, Feig BW: Hemangiopericytoma: a 20-year single-institution experience. Ann Surg Oncol 1998, 5:350-5.
• [13]Espat NJ, Lewis JJ, Leung D, Woodruff JM, Antonescu CR, Shia J, Brennan MF: Conventional hemangiopericytoma: modern analysis of outcome. Cancer 2002, 95:1746-51.
• [14]Magdeleinat P, Alifano M, Petino A, Le Rochais JP, Dulmet E, Galateau F, Icard P, Regnard JF: Solitary fibrous tumors of the pleura: clinical characteristics, surgical treatment and outcome. Eur J Cardiothorac Surg 2002, 21:1087-93.
• [15]Galanis E, Buckner JC, Scheithauer BW, Kimmel DW, Schomberg PJ, Piepgras DG: Management of recurrent meningeal hemangiopericytoma. Cancer 1998, 82:1915-20.
• [16]Soyuer S, Chang EL, Selek U, McCutcheon IE, Maor MH: Intracranial meningeal hemangiopericytoma: the role of radiotherapy: report of 29 cases and review of the literature. Cancer 2004, 100:1491-7.
• [17]McMaster MJ, Soule EH, Ivins JC: Hemangiopericytoma. A clinicopathologic study and long-term followup of 60 patients. Cancer 1975, 36:2232-44.
• [18]Muñoz AK, Berek JS, Fu YS, Heintz PA: Pelvic hemangiopericytomas: a report of five cases and literature review. Gynecol Oncol 1990, 36:380-2.
• [19]Schiariti M, Goetz P, El-Maghraby H, Tailor J, Kitchen N: Hemangiopericytoma: long-term outcome revisited. Clinical article. J Neurosurg 2011, 114:747-55.
• [20]Guillerme F, Truntzer P, Prim N, Chenard MP, Voirin J, Noël G: Solitary fibrous tumors: Case report of a late relapse. Cancer Radiother 2011, 15:330-3.
• [21]Park CK, Lee DH, Park JY, Park SH, Kwon KY: Multiple recurrent malignant solitary fibrous tumors: long-term follow-up of 24 years. Ann Thorac Surg 2011, 91:1285-8.
• [22]Mohamed H, Mandal AK: Natural history of multifocal solitary fibrous tumors of the pleura: a 25-year follow-up report. J Natl Med Assoc 2004, 96:659-62.
• [23]Tzelepi V, Zolota V, Batistatou A, Fokaefs E: Solitary fibrous tumor of the urinary bladder: report of a case with long-term follow-up and review of the literature. Eur Rev Med Pharmacol Sci 2007, 11:101-6.
• [24]Fujita I, Kiyama T, Chou K, Kanno H, Naito Z, Uchida E: A case of metastatic hemangiopericytoma occurring 16 years after initial presentation: with special reference to the clinical behavior and treatment of metastatic hemangiopericytoma. J Nihon Med Sch. 2009, 76:221-5.
• [25]Hiraki A, Murakami T, Aoe K, Matsuda E, Maeda T, Uemori Y, Ueoka K: Recurrent superior mediastinal primary hemangiopericytoma 23 years after the complete initial excision: a case report. Acta Med Okayama 2006, 60:197-200.
• [26]Suzuki H, Haga Y, Oguro K, Shinoda S, Masuzawa T, Kanai N: Intracranial hemangiopericytoma with extracranial metastasis occurring after 22 years. Neurol Med Chir (Tokyo) 2002, 42:297-300.
• [27]Kim JH, Jung HW, Kim YS, Kim CJ, Hwang SK, Paek SH, Kim DG, Kwun BD: Meningeal hemangiopericytomas: long-term outcome and biological behavior. Surg Neurol 2003, 59:47-53. discussion 53–4
• [28]Hanau CA, Miettinen M: Solitary fibrous tumor: histological and immunohistochemical spectrum of benign and malignant variants presenting at different sites. Hum Pathol 1995, 26:440-9.
• [29]Kaplan WE, Meier P: Non parametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-81.
• [30]Collini P, Negri T, Barisella M, Palassini E, Tarantino E, Pastorino U, Gronchi A, Stacchiotti S, Pilotti S: High-grade sarcomatous overgrowth in solitary fibrous tumours: A clinico-pathological study of 10 cases. Am J Surg Path 2012, 36:1202-15.
• [31]Fisher JH: Hemangiopericytoma: a review of twenty cases. Can Mes Assoc J 1960, 83:1136-39.
• [32]Jha N, McNeese M, Barkley HT, Kong J: Does radiotherapy have a role in hemangiopericytoma management? Report of 14 new cases and review of literature. Int J Radiat Oncol Biol Phys 1987, 13:1399-402.
• [33]Dube VE, Paulson JE: Metastatic hemangiopericytoma cured by radiotherapy. A case report. J Bone Joint Surg Am 1974, 56:833-55.
• [34]Friedman M, Egan JW: Irradiation of hemangiopericytoma of Stout. Radiology 1960, 74:721-30.
• [35]Mira JH, Chu FCH, Fortner JG: The role of radiotherapy in the management of malignant hemangiopericytoma: report of eleven new cases and review of literature. Cancer 1977, 30:1254-9.
• [36]Stacchiotti S, Negri T, Palassini E, Conca E, Gronchi A, Morosi C, Messina A, Pastorino U, Pierotti MA, Casali PG, Pilotti S: Sunitinib malate and figitumumab in solitary fibrous tumor: patterns and molecular bases of tumor response. Mol Cancer Ther 2010, 9:1286-97.
• [37]Park MS, Patel SR, Ludwig JA, Trent JC, Conrad CA, Lazar AJ, Wang WL, Boonsirikamchai P, Choi H, Wang X, Benjamin RS, Araujo DM: Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor. Cancer 2011, 117:4939-47.
• [38]Quek R, Wang Q, Morgan JA, Shapiro JI, Butrynsky JE, Ramaiya N, Huftalen T, Jederlinic N, Manola J, Wagner AJ, Demetri GD, George S: Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors. Clin Cancer Res 2011, 17:871-9.
• [39]Stacchiotti S, Negri T, Libertini M, Palassini E, Marrari A, De Troia B, Gronchi A, Dei Tos AP, Morosi C, Messina A, Pilotti S, Casali PG: Sunitinib malate in solitary fibrous tumor (SFT). Ann Oncol 2012, 23(12):3171-9.